H
LA class I molecules bind and present antigenic peptides to CTLs (1, 2) . Bound peptides form an integral part of the molecule and facilitate stable expression at the cell surface (3, 4) . Antigenic peptides eluted from murine H-2 class I molecules and HLA-A*0201 have been sequenced. These analyses reveal that naturally processed peptides are generally heterogenous in character but restricted in length to eight or nine amino acid residues. Furthermore, for any given allele certain peptide residues show limited heterogeneity, allowing the definition of allele-specific sequence motifs in terms of these "anchor" residues (5) (6) (7) (8) . Examination of the structure of antigenic peptides, represented as "extra density" in the x-ray crystallographic solutions for HLA-A*0201 and A'6801, suggests that the peptide amino acid side chains are positioned in the dass I molecule to interact with specificity pockets that extend from the peptide binding groove (9) (10) (11) .
In light of these findings, we reasoned that peptide anchor residues must interact with class I molecules through specificity pockets that are optimized to bind their side chains, and other residue side chains may interact with pockets that are less discriminating. Pockets binding anchoring side chains would be specialized structures within the peptide binding groove that might be maintained during evolution because of their important functional role. To test this hypothesis, we first examined the primary structures of 61 HLA class I molecules and mapped their'polymorphisms into the six specificity ~ pockets revealed in the peptide binding groove of the 2.6-Arefined structure of HLA-A*0201 (11, 12) . This analysis demonstrated that all six pockets contain highly polymorphic residues and that there is little tendency for major alleles to share similar pocket structures (data not shown). We then chose to examine the subtypes of major alleles, as products of relatively recent evolutionary change.
We report our findings with respect to seven HLA-B27 subtypes (12) (13) (14) . Sequence comparison reveals eleven residues that are polymorphic among the subtypes, and these map to five of the six specificity pockets. One pocket, the B ("45") pocket, is totally conserved among all HLA-B27 subtypes. Further analysis by site-directed mutagenesis shows this region, and the glutamine residue at position 45 in particular, play a critical role in cell-surface expression, peptide binding, and antigen presentation by HLA-B*2705. We predict that B'2705,8; Cw2) , DB (A25,32; B'2705,18), and WG (A3,A23; BwS0,Bw55; Cw3,Cw6). Other EBV lines used were: JY (A2,2; B7,7;), BL, EBV (A1,2;BT,37), HOM2 (A3; B'2705), JESTHOM (A2; B'2705), C1R ( , , Cw4), B27CIK (-, B'2705, Cw4), LH (A24; B'2701,8; Cwl,7), PG (All,31; B'2705,35; Cw2,4), WE1 (All,24; B*2704,w62; Cw6), and LIE (A2,11; B'2706,5; Cw3).
Mutagenesis and Transfection.
HLA-B27 single residue mutants (see Table 3 ) were created by site-directed mutagenesis of the HLA-B'2705 gene obtained from Dr. Joel Tautog (University of Texas Southwestern Medical Center, Dallas, TX), as a 6.5-kb EcoRI fragment subcloned in pUC19. Three constructs were made. First, the HLA-B*2705 gene was shortened in the 3' untranslated region by restriction enzyme digestion with BstEII and HinclI (in the 3' polylinker of pUC19), Klenow DNA polymerase I fill in, and subsequent religation. This served to shorten the gene to 3.9 kb and to remove an inconvenient second 3' DralII site. Next the exons encoding the leader sequence, c~ and c~2 domains were subcloned as a 2-kb EcoR.I/AvrlI fragment into EcoRI/XbaI cut M13mp18 vector, and the exons encoding the c~3, transmembrane, and cytoplasmic domains were subcloned as a 2.2-kb KpnI/Sspl fragment into KpnI/HinclI cut M13mp18. Mutagenesis was then effected on these fragments in M13mp18 by the method of Kunkel (15) using the Muta-gene in vitro mutagenesis kit (Bio-Rad Laboratories, Richmond, VA). Mutated c~1 and o~2 exons were subcloned back into the 3.9-kb HLA-B27/pUC19 construct on a 1.8-kb EcoKI/DralII fragment, and mutated c~3 exons were subcloned as a 1.8-kb DralII/BstXI fragment.
Mutant HLA-B27 genes were then subcloned into pHEBO (16) as a 4.0-kb HindlII (in the 3' polylinker)/FspI (150 bp 5' in the pUC19 sequence) fragment, pHEBO was prepared by digestion with SalI, blunt-ended with Klenow DNA polymerase I, and digestion with HindlII, before gel purification. Mutant genes were electroporated into CIR cells as previously described, and selection with Hygromycin was initiated 3 d later (17, 18) . Mutant genes were verified by DNA sequencing.
FACS | Analysis. Levels of cell surface HLA class I expression of all cell lines was determined within 72 h of the performance of both peptide binding and CTL assays. This was done by FACScan | analysis, using fluorescein-conjugated antibodies W6/32 and PA2.6 (both monomorphic anti-HLA class I antibodies), ME1 (anti-HLA-B27, B7, and Bw42) and B27M1 (anti-HLA-B27) (19) (20) (21) . In addition, CD8 expression by all CTL lines was verified by FACScan | using fluorescein-conjugated antibodies OKT4 (anti-CD4) and OKT8 (anti-CD8).
Synthetic Peptides. A peptide (SRYWAIRTRSGG) corresponding to the sequence of influenza A nucleoprotein (383-394) (NP1) 1 (22) was synthesized by the solid phase method using Fmoc chemistry.
Generation ofAutologous CTL. PBL from the HLA-B27-positive individuals were stimulated in primary culture with 5 #g/ml of (NP1) peptide in RPMI 1640 supplemented with 2-mM r-glutamine, 10% FCS (Hyclone Laboratories, Logan, UT). After 1 wk, cultures were restimulated with 5 x 10 s irradiated (10,000 tad) autologous EBV-transformed cells plus 5/zg/ml NP1, and were supplemented with T cell-conditioned medium every 7 d (23) with either the autologous EBV cell line or HOM2 plus NP1 peptide.
Generation ofAllogeneic CTL. PBL from a normal donor WG
were cultured with irradiated (10,000 tad) B27CIR cells in RPMI 1640 supplemented with 10% FCS and 2 mM glutamine. After 7 d, the cultures were restimulated with a different irradiated HLA1Abbreviation used in this paper: NP1, influenza A nucleoprotein.
B27-positive EBV-transformed cell line and were supplemented with T cell conditioned medium (23) . After 3 wk of culture, the line was cloned by limiting dilution (24) .
Assay of CTL. CTL activity was measured using a standard 4-h SlCr release assay (23) . Unless otherwise noted, target cells were incubated for 2 h with 200/zCi of SlCr. Targets were then washed three times, counted, and plated in the presence of I or 2/zg/ml NP1 for the duration of the assay.
Binding Assay. Peptide NP1 was iodinated by the Chloramine T method and free 12sI separated from the iodinated peptide by means of a Sep-pak C18 column as previously described (25) . In the experiment shown in Fig. 2 a, 200/~g NP1 was iodinated with 6.5 mCi 125I and in that shown in Fig. 2 b, 20 #g was iodinated with 2 mCi 12sI.
nSI-NP1 peptide was added to 500-/zl aliquots of 2.5 x 106 cells and incubated for 6 h at 37~ The cells were then washed, lysed, and the HLA-class I molecules immunoprecipitated with the W6/32 antibody as previously described (25) . The amount of bound peptide was then assessed by measuring the 12si radioactivity coprecipitated with the HLA class I molecules using a 1260 Multi gamma counter (LKB Instruments, Inc., Gaithersburg, MD).
Results

Conservation of the B Specificity
Pocket among HLA-B27 Subtypes. The 2.6-A refined crystallographic structure of HLA-A2 reveals six specificity pockets (labeled A-F) located in the peptide binding groove, which are thought to interact with amino acid side chains of bound peptides (Fig. 1 a) (11) . Comparison of the sequences of the known HLA-B27 subtypes shows that variation between the subtypes occurs in five of the six pockets: A, C, D, E, and F (Table 1 ). In contrast, the 10 residues comprising the core of the B pocket (positions 9, 24, 34, 45, and 67) and its environs (positions 7, 63, 66, 70, and 99) are totally conserved among the subtypes (Table 2 ) and the HLA-B27 combination of 10 residues is not found in the B pocket of any other HLA class I sequence. This finding is significant as the B pocket is highly polymorphic in all classical class I heavy chains, especially in the products of the HLA-B locus, strongly suggesting that the B pocket has been actively conserved throughout the recent evolution of HLA-B27 ( Table 2) .
Mutagenesis of the B Pocket of HLA-B27. Conservation of the B pocket among subtypes suggests its structure is vital to the function of the HLA-B27 molecule. To test this hypothesis, HLA-B27 point mutants with changes at positions 9, 45, and 67 in the B pocket and position 70 at its rim, were derived. Further mutants with substitutions at positions 71 and 77 (o~1 domain), 97 (oe2 domain), and at position 227 (c~3 domain) were included for comparison (Table  3) . In each case, the amino acid introduced by mutagenesis was one that occurs naturally in other HLA class I molecules (see Table 2 ). Mutant genes were electroporated into C1R cells (17) , and expression assessed with the monomorphic anti-HLA class I mAb W6/32, as well as with the anti-HLA-B27 antibodies ME1 and B27M1 (19) (20) (21) . Comparable expression of each mutant was detected with all three antibodies, with the exception of the 45K mutant, which was detected at levels 12-15-fold lower than wild-type with ME1 and was
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Conserved undetectable with B27M1, and the 67Y mutant, which was not detectable with any of the antibodies (Table 3) . Electroporation was repeated on at least three occasions with similar results. Lysine at position 45 occurs naturally in many HLA-B locus products including HLA-B*4001, B'4002, B'4101, B'4401, B'4701, and B'4901, and tyrosine at position 67 occurs in HLA-B*0701, B'4201, and B'4601 (12) . Clearly, expression of the HLA-B27 molecule is sensitive to mutations within the B pocket, however the finding that the 45M, 67A, and 67S mutants were expressed demonstrates that some mutations are permissible at these positions.
Influenza Nucleolorotein Peptide (383-394) Binding to Mutant HLA-B27 Molecules. NP1 (383-394) is recognized by CTL
when bound and presented by HLA-B*2705 molecules (22) . 811 Buxton et al.
Furthermore, we have shown that radioiodinated-NPl binds directly to a large proportion of cell surface HLA-B*2705 molecules in a peptide-and aUele-specific fashion in culture (25) . We therefore tested the effects of point mutations in the B pocket of HLA-B*2705 on the binding of the NP1 peptide. The results show that all mutations within the B pocket (9Y; 45M; 67A; and 67S) diminish peptide binding (Fig. 2 ). These effects were seen at two different peptide concentrations -5/zg/ml (Fig. 2 a) and 50/~g/ml ( Fig. 2 b) , and ~>90% inhibition of binding was observed. The 70Q mutation at the rim of the B pocket, and also the 227K and 77S mutations had no effect on peptide binding. The 97R mutation, on the other hand, also decreased binding by ~>90%. Surprisingly, the mutation at position 71, a residue The table displays only the residues that differ among the seven subtypes of HLA-B27, and the pockets (A-F) to which they map in the 2.6-A refined structure of HLA-A2.
that is not thought to directly contribute to the peptide binding groove, reproducibly reduced binding by as much as 70%.
NPl-specific CTL Lysis of HLA-B*2705
Point Mutants. We next tested whether recognition of HLA-B27 by NPl-specific CTL was similarly affected by point mutations in the B pocket. CTL lines generated from HLA-B*2705-positive donors were shown to be both peptide-and allele-specific by their requirement for the presence of NP1 for lysis, and their inability to lyse cell lines bearing other HLA-B27 subtypes (HLA-B'2701, 02, 04, and 06) (Fig. 3) .
Peptide-specific lysis of cells expressing point mutants of HLA-B*2705 was tested using CTL lines from two donors, RB and DB (Fig. 4) . The 67A and 67S mutants, which did not bind peptide (Fig. 2) , were not lysed by NPl-specific CTL. The 70Q mutation at the rim of the B pocket, which did not affect the extent of NP1 peptide binding, reduced lysis by both CTL lines by about 50%. The 9Y and 45M mutants, which bound NP1 peptide poorly, were lysed about 50% as well as wild-type HLA-B*2705-bearing cells by the DB CTL line. This latter result suggested that the 45M and 9Y mutations do not abrogate binding, but reduce it to below the limit of detection in the binding assay, which we estimate to be about 1,000 peptide molecules/cell. This hypothesis was tested in two ways. First, we examined the requirement for the presence of NP1 peptide throughout the 4-h time period of the CTL assay. Cells expressing the 45M and 9Y mutants and control target cells were cultured overnight in the presence of NP1 peptide to allow a steady-state level of peptide binding to be reached, and then washed thoroughly before adding CTL and, to half of the assay, additional NP1 peptide. Cells expressing wild-type HLA-B*2705 were lysed equally well, regardless of the presence or absence of NP1 during the CTL assay, and both the 45M and 9Y mutants were lysed less well when NP1 was not included throughout the 4-h duration of the 51Cr release assay (Fig. 5) . Second, titration revealed that optimum lysis of cells expressing the 45M and 9Y mutants of HLA-B* 2705 required, respectively, 50 and 20 times more NP1 peptide in the assay, when compared with wild-type HLA-B*2705 (data not shown). These results indicate the kinetics of dissociation and/or association of the NP1 peptide with the wild-type and mutant HLA-B27 molecules are significantly different, with the mutants having a lower affinity for peptide. This is compatible with the conclusion that NP1 binds to the mutant HLAoB27 molecules at a level that is sufficient to trigger CTL, hut is undetectable in the binding assay (29, 30) .
The 45M mutation had a surprising effect on recognition of HLA-B27 by the RB CTL line. This CTL line lysed cells expressing the 45M mutant in a NPl-peptide independent fashion (Fig. 5 b) . As the amino acid at position 45 is not assigned to interact directly with the CTL TCR, the implication of this observation is that the mutation alters the molecule in such a manner that an endogenous peptide bound to the 45M mutant or empty 45M molecules, resembles the complex of wild-type HLA-B*2705 and NP1 peptide (9) .
Point mutations not in the B pocket also had diverse effects upon CTL recognition. The substitution of lysine at position 227 in the ol3 domain prevents CD8 binding (18, 31) . Cells expressing the 227K mutant were not lysed by either CTL line, demonstrating their CD8 dependence. The 71T mutation, on the other hand, abrogated recognition by the DB CTL line and decreased that of the RB CTL line by 60%, implying residues with side chains not assigned to interact with either peptide or TCR can affect both peptide binding and CTL recognition. The 77S mutation, like the 70Q mutant, did not affect the amount of peptide binding but did reduce CTL recognition by about 50%, and the 97R mutant neither bound significant amounts of peptide, nor was lysed by the CTL lines.
In conclusion, these results indicate the 67A, 67S, and 97R mutations reduce CTL recognition by abrogating NP1 peptide binding. The 9Y, 45M, and 71T mutations reduce the extent of peptide binding and have variable effects on T cell
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Conserved B Anchoring B ("45") Pocket of HLA-B27 
The table shows the 10 amino acid residues that influence the nature of the B pocket in HLA-A2 and how they vary among 61 HLA class I sequences. 
Discussion
These experiments reveal a major role for the residue at position 45, and the B pocket in general, in HLA-B27 function (Table 4 ). Initially we observed that replacing the negatively charged glutamic acid residue at position 45 with positively charged lysine (as found in HLA-B*4001, B'4002, B'4101, B'4401, B'4701, and B'4901) resulted in a 12-15-fold decrease in cell surface expression, and the more conservative change to methionine (as found in HLA-A locus products) was expressed well. However, the 45M mutation greatly reduced the binding affinity for a known HLA-B*2705 binding peptide (NP1), although not to the point where CTL recognition was eliminated. Two further observations suggested that the 45M mutation also affected presentation of endogenously processed peptides. First, we found that the 45M mutant is recognized by the NPl-peptide-specific RB CTL line in a peptide-independent fashion, and second, it abrogated recognition by four of five alloreactive clones, and no other mutation affected recognition by more than a single clone. As the residue at position 45 is not assigned to interact with the TCR (9-11), and since alloreactive clones are often dependent on the nature of the endogenously bound peptide (32), these findings are best explained by an indirect effect of the 45M mutation on the nature or conformation of the endogenous peptide, such that it mimics the HLA-B*2705 molecule complexed to NP1 peptide, and is no longer recognized by the majority of alloreactive clones.
The importance of the peptide/B pocket interaction is further substantiated by the finding that mutations of other residues in the B pocket also markedly affect HLA-B27 function. Relatively conservative changes at positions 67 and 9 (67S, 67A, and 9Y) decreased NP1 peptide binding by >90%.
In the case of the mutations at position 67, there was a concomitant loss of NPl-specific CTL recognition of the mutant HLA-B*2705 molecules, suggesting an absolute loss of peptide binding, and the mutation at position 9 only decreased the affinity of binding as NPl-specific CTL, which still recognized the mutant in a peptide dependent fashion. Furthermore, we found that changing cysteine at position 67 to tyrosine caused a loss of HLA-B*2705 expression in C1R cells. Tyrosine at this position is found in HLA-B*0701, B'4201, and B'4601, and is predicted to block access to the B pocket (10) . That two mutations (45K and 67Y) which radically alter the B pocket lead to a decrease in cell surface expression is remarkable. We favor the explanation that there is a relative lack of endogenous peptides able to bind these mutant molecules with sufficient affinity to stabilize their cell surface expression, although other possibilities cannot be formally excluded. It is interesting that E1-Zaatari et al. (33) showed that the 67Y mutant molecule is expressed in mouse L cells, albeit with a loss of the overlying ME1 antibody epitope. We confirmed these results on transfecting our 67Y mutant construct into human-flzm expressing L cells (data not shown). These findings may be explained by the presence of a endogenous peptide in mouse, and not human 814 Conserved cells, that is able to bind and stabilize the 45M mutant molecule.
That the residue at position 45 plays a major role in HLA-B'2705 function can be explained in terms of the structure of HLA-B* 2705, modeled on the known structures of HLA-A*0201 and HLA-A*6801 (9) (10) (11) . In these molecules, the core of the B pocket is formed by hydrophobic residues (9F or Y; 24A; 45M; 67V and 34V) and the pocket is thought to bind either a leucine or isoleucine side chain. Site-directed mutagenesis studies of HLA-A*0201 reveals that mutations in the B pocket also markedly affect peptide-specific and alloreactive CTL recognition (34) . In comparison, most of the residues lining the core of the B pocket in HLA-B27 are hydrophilic (9H, 24T, and 67C) with the negatively charged 45E side chain situated at the apex of the pocket. This has 815 Buxton et al.
led to the suggestion that the B pocket may bind a positively charged side-chain (e.g., histidine, arginine, or lysine) that forms a salt bridge with the 45 glutamate side chain (10) . Such a salt bridge may drastically increase the binding affinity of the side chain in the pocket, and effectively anchor the peptide in the groove. Mutations at position 45 would prevent the formation of the salt bridge and decrease the affinity of peptide binding without affecting the conformation of the bound peptide. Our finding that NPl-peptide binding to the 45M mutant could not be detected in the binding assay, yet was detected by NPl-peptide specific CTL, supports this model. Mutations that dramatically affect peptide binding affinity would also affect endogenous peptide selection by HLA-B*2705. Again, this is supported by our finding that the 45M mutant had a major effect on alloreactive CTL recognition.
Mutations outside of the B pocket also had diverse effects on HLA-B27 function and dearly showed that the B pocket is not the only feature of the HLA-B27 groove that determines binding and presentation of the NP1 peptide. Indeed, even changing a residue that is not assigned to interact with either the TCR or the peptide (threonine for the natural alanine at position 71) reduced peptide binding and abrogated recognition by the DB NPlospecific CTL line. This residue is polymorphic in the products of HLA-B locus genes and clearly must have an indirect effect on peptide binding and presentation, probably by affecting the side chain conformation of adjacent amino acid residues that impact on the binding groove. Next, we found that changing the asparagine residue for aspartate at position 97 both abrogated NP1 binding and NPl-specific CTL recognition, suggesting an absolute loss of binding. Asparagine at position 97 forms part of the core of both the C and E pockets, and our results suggest that interactions with these pockets may also critically affect peptide binding. Mutations at the rim of the B pocket (70Q) and the side wall of the F pocket (77S), on the other hand, had no affect on NP1 peptide binding but did reduce NP1-specific CTL recognition. This implies that these residues may not be involved in determining which peptides bind to HLA-B*2705, but do affect T cell recognition, probably by changing the conformation of the peptide in the groove.
In these studies, widely different results were obtained with the various functional assays used to analyze the point mutants of HLA-B*2705. The NPl-peptide binding assay was very sensitive to changes in the amount and affinity of peptide binding to HLA-B*2705, but was a poor indicator of low-level binding. Peptide-specific CTL detected weak peptide binding but gave no indication of subtle changes in peptide binding unless careful titrations of limiting amounts of peptide were performed. Thus the two assays complement each other by their differing ranges of sensitivity. In contrast, aUoreactive CTL were generally insensitive to the point mutations we derived, with the marked exception of the 45M mutant. These findings may be explained in terms of the different reactivities of peptide-specific and aUoreactive CTL. Epitopes on both the presenting class I molecule and endogenous peptide(s) contribute to the alloantigen, and recognition by peptide-specific CTL depends on bound peptide. The table summarizes the data shown in Table 3 indicated that the mechanism of the binding assay involves the interaction of the radiolabeled peptide with an apparently large number of "empty" HLA molecules on the cell surface. The CTL data here complements these results and suggests that most point mutations do not alter the stability of the empty molecules, or the proportion of molecules that arrive at the cell surface empty. 817 Buxton et al. In conclusion, we have shown that B pocket is highly conserved among the HLA-B27 subtypes, and that it plays an important role in the expression of HLA-B*2705 and in the presentation of both endogenous and exogenous peptides. In light of these findings, we predict that the B pocket anchors an antigenic peptide amino acid side chain that will be found in a similar position in most endogenously-processed peptides bound by HLA-B*2705. Furthermore, the conservation of the B pocket among HLA-B27 subtypes suggests that peptides bound to all of these will carry the same motif. Wiley and colleagues have recently solved the HLA-B27 x-ray crystallographic structure, emphasizing the importance of the B pocket (35a). Furthermore, they have sequenced 11 naturally processed peptides isolated from HLA-B27, and found that 818 all of these have an arginine residue at position 2 (35b). Together, these observations have implications for the association of HLA-B27 with Ankylosing Spondylitis, a disease which is thought to be mediated by CTL that recognize a self-peptide presented by HLA-B27 (36) . One argument against this "arthritogenic peptide" hypothesis is the finding that multiple subtypes (HLA-B*2702; 04, 05, and 06) are disease associated, and differ greatly in peptide binding, alloreactive~CTL and peptide-specific CTL recognition (22, 25, 37) . Our findings suggest that these subtypes all bind peptides with at least one common anchor motif, rendering it more likely that a single arthritogenic peptide may be presented to CTL by multiple HLA-B27 subtypes, thereby explaining the shared disease association.
